For example, malignant neuroendocrine tumors occasionally show low uptake on somatostatin scintigraphy and high uptake on FDG-PET [18, 19] because of SSTR2 deficiency and high glucose transporter [19, 20] or modified glucose metabolism, respectively. Here, SSTR2 is linked to neuroendocrine neoplasm.